Alembic Pharmaceuticals Limited — Board Meeting, 06-05-2025: Outcome of Board Meeting

Alembic Pharmaceuticals has announced a board meeting where it approved the audited consolidated financial results for the quarter and financial year ended March 31, 2025. Consolidated revenue rose 7% YoY to Rs. 6,672 Cr, while net profit dipped 5% to Rs. 583 Cr. EBITDA margin held steady at 15.8%. A dividend of Rs. 11 per share (550%) was proposed, matching last year. The company received an insurance claim of Rs. 83.6 Cr for Sikkim plant flood losses. New statutory auditors KKC & Associates LLP and secretarial auditors Samdani Shah & Kabra were appointed for five years.